Literature DB >> 34289969

Biomarkers of Inflammation and Oxidative Stress among Adult Former Smoker, Current E-Cigarette Users-Results from Wave 1 PATH Study.

Carol H Christensen1, Joanne T Chang2, Brian L Rostron2, Hoda T Hammad2, Dana M van Bemmel2, Arseima Y Del Valle-Pinero2, Baoguang Wang2, Elena V Mishina2, Lisa M Faulcon2, Ana DePina2, La'Nissa Brown-Baker2, Heather L Kimmel3, Elizabeth Lambert3, Benjamin C Blount4, Huber W Vesper4, Lanqing Wang4, Maciej L Goniewicz5, Andrew Hyland5, Mark J Travers5, Dorothy K Hatsukami6, Raymond Niaura7, K Michael Cummings8, Kristie A Taylor9, Kathryn C Edwards9, Nicolette Borek2, Bridget K Ambrose2, Cindy M Chang2.   

Abstract

BACKGROUND: Former smokers who currently use e-cigarettes have lower concentrations of biomarkers of tobacco toxicant exposure than current smokers. It is unclear whether tobacco toxicant exposure reductions may lead to health risk reductions.
METHODS: We compared inflammatory biomarkers (high-sensitivity C-reactive protein, IL6, fibrinogen, soluble intercellular adhesion molecule-1) and an oxidative stress marker (F2-isoprostane) among 3,712 adult participants in Wave 1 (2013-2014) of the Population Assessment of Tobacco and Health Study by tobacco user groups: dual users of cigarettes and e-cigarettes; former smokers who currently use e-cigarettes-only; current cigarette-only smokers; former smokers who do not currently use any tobacco; and never tobacco users. We calculated geometric means (GM) and estimated adjusted GM ratios (GMR).
RESULTS: Dual users experienced greater concentration of F2-isoprostane than current cigarette-only smokers [GMR 1.09 (95% confidence interval, CI, 1.03-1.15)]. Biomarkers were similar between former smokers who currently use e-cigarettes and both former smokers who do not use any tobacco and never tobacco users, but among these groups most biomarkers were lower than those of current cigarette-only smokers. The concentration of F2-isoprostane decreased by time since smoking cessation among both exclusive e-cigarette users (P trend = 0.03) and former smokers who do not currently use any tobacco (P trend = 0.0001).
CONCLUSIONS: Dual users have greater concentration of F2-isoprostane than smokers. Exclusive e-cigarette users have biomarker concentrations that are similar to those of former smokers who do not currently use tobacco, and lower than those of exclusive cigarette smokers. IMPACT: This study contributes to an understanding of the health effects of e-cigarettes. ©2021 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34289969      PMCID： PMC8500540          DOI： 10.1158/1055-9965.EPI-21-0140

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN： 1055-9965            Impact factor:   4.090


  43 in total

1.  Association of smoking and electronic cigarette use with wheezing and related respiratory symptoms in adults: cross-sectional results from the Population Assessment of Tobacco and Health (PATH) study, wave 2.

Authors:  Dongmei Li; Isaac K Sundar; Scott McIntosh; Deborah J Ossip; Maciej Lukasz Goniewicz; Richard J O'Connor; Irfan Rahman
Journal:  Tob Control       Date:  2019-02-13       Impact factor: 7.552

2.  Elevated plasma 8-iso-prostaglandin F2α levels in human smokers originate primarily from enzymatic instead of non-enzymatic lipid peroxidation.

Authors:  Thomas J van 't Erve; Fred B Lih; Maria B Kadiiska; Leesa J Deterding; Ronald P Mason
Journal:  Free Radic Biol Med       Date:  2017-11-21       Impact factor: 7.376

3.  Cigarette smoking and variations in systemic immune and inflammation markers.

Authors:  Meredith S Shiels; Hormuzd A Katki; Neal D Freedman; Mark P Purdue; Nicolas Wentzensen; Britton Trabert; Cari M Kitahara; Michael Furr; Yan Li; Troy J Kemp; James J Goedert; Cindy M Chang; Eric A Engels; Neil E Caporaso; Ligia A Pinto; Allan Hildesheim; Anil K Chaturvedi
Journal:  J Natl Cancer Inst       Date:  2014-10-01       Impact factor: 13.506

4.  Cigarette smoking and cardiovascular events: role of inflammation and subclinical atherosclerosis from the MultiEthnic Study of Atherosclerosis.

Authors:  John W McEvoy; Michael J Blaha; Andrew P DeFilippis; Joao A C Lima; David A Bluemke; W Gregory Hundley; James K Min; Leslee J Shaw; Donald M Lloyd-Jones; R Graham Barr; Matthew J Budoff; Roger S Blumenthal; Khurram Nasir
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-01-08       Impact factor: 8.311

Review 5.  Mechanisms of toxicity and biomarkers of flavoring and flavor enhancing chemicals in emerging tobacco and non-tobacco products.

Authors:  Gurjot Kaur; Thivanka Muthumalage; Irfan Rahman
Journal:  Toxicol Lett       Date:  2018-02-23       Impact factor: 4.372

6.  Smoking cessation and cardiovascular disease risk factors: results from the Third National Health and Nutrition Examination Survey.

Authors:  Arvind Bakhru; Thomas P Erlinger
Journal:  PLoS Med       Date:  2005-06-28       Impact factor: 11.069

7.  Classifying oxidative stress by F2-isoprostane levels across human diseases: A meta-analysis.

Authors:  Thomas J van 't Erve; Maria B Kadiiska; Stephanie J London; Ronald P Mason
Journal:  Redox Biol       Date:  2017-03-28       Impact factor: 11.799

8.  Fourth generation e-cigarette vaping induces transient lung inflammation and gas exchange disturbances: results from two randomized clinical trials.

Authors:  Martin Chaumont; Philippe van de Borne; Alfred Bernard; Alain Van Muylem; Guillaume Deprez; Julien Ullmo; Eliza Starczewska; Rachid Briki; Quentin de Hemptinne; Wael Zaher; Nadia Debbas
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-02-06       Impact factor: 5.464

9.  Correlation between biomarkers of exposure, effect and potential harm in the urine of electronic cigarette users.

Authors:  Shane Sakamaki-Ching; Monique Williams; My Hua; Jun Li; Steve M Bates; Andrew N Robinson; Timothy W Lyons; Maciej Lukasz Goniewicz; Prue Talbot
Journal:  BMJ Open Respir Res       Date:  2020-02

10.  Comparison of Nicotine and Toxicant Exposure in Users of Electronic Cigarettes and Combustible Cigarettes.

Authors:  Maciej L Goniewicz; Danielle M Smith; Kathryn C Edwards; Benjamin C Blount; Kathleen L Caldwell; Jun Feng; Lanqing Wang; Carol Christensen; Bridget Ambrose; Nicolette Borek; Dana van Bemmel; Karen Konkel; Gladys Erives; Cassandra A Stanton; Elizabeth Lambert; Heather L Kimmel; Dorothy Hatsukami; Stephen S Hecht; Raymond S Niaura; Mark Travers; Charles Lawrence; Andrew J Hyland
Journal:  JAMA Netw Open       Date:  2018-12-07
View more
  2 in total

1.  Cardiovascular Outcomes among Combustible-Tobacco and Electronic Nicotine Delivery System (ENDS) Users in Waves 1 through 5 of the Population Assessment of Tobacco and Health (PATH) Study, 2013-2019.

Authors:  Martin C Mahoney; Cheryl Rivard; Heather L Kimmel; Hoda T Hammad; Eva Sharma; Michael J Halenar; Jim Sargent; K Michael Cummings; Ray Niaura; Maciej L Goniewicz; Maansi Bansal-Travers; Dorothy Hatsukami; Diann Gaalema; Geoffrey Fong; Shannon Gravely; Carol H Christensen; Ryan Haskins; Marushka L Silveira; Carlos Blanco; Wilson Compton; Cassandra A Stanton; Andrew Hyland
Journal:  Int J Environ Res Public Health       Date:  2022-03-31       Impact factor: 3.390

2.  Understanding heterogeneity among individuals who smoke cigarettes and vape: assessment of biomarkers of exposure and potential harm among subpopulations from the PATH Wave 1 Data.

Authors:  Pavel N Lizhnyak; Brendan Noggle; Lai Wei; Jeffery Edmiston; Elizabeth Becker; Ryan A Black; Mohamadi Sarkar
Journal:  Harm Reduct J       Date:  2022-08-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.